Evidence map›Paper›PMID 39700101›Full record

ArticlePloS one2024

A Monte-Carlo planning strategy for medical follow-up optimization: Illustration on multiple myeloma data.

Benoîte de Saporta, Aymar Thierry d'Argenlieu, Régis Sabbadin, Alice Cleynen

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Benoîte de SaportaIMAG, CNRS, Univ Montpellier, Montpellier, France.
Aymar Thierry d'ArgenlieuIMAG, CNRS, Univ Montpellier, Montpellier, France.ORCID 0009-0000-2427-889X
Régis SabbadinINRAE-MIAT, Univ Toulouse, Toulouse, France.
Alice CleynenIMAG, CNRS, Univ Montpellier, Montpellier, France.ORCID 0000-0001-8083-0204

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Designing patient-specific follow-up strategies is key to personalized cancer care. Tools to assist doctors in treatment decisions and scheduling follow-ups based on patient preferences and medical data would be highly beneficial. These tools should incorporate realistic models of disease progression under treatment, multi-objective optimization of treatment strategies, and efficient algorithms to personalize follow-ups by considering patient history. We propose modeling cancer evolution using a Piecewise Deterministic Markov Process, where patients alternate between remission and relapse phases, and control the model via long-term cost function optimization. This considers treatment side effects, visit burden, and quality of life, using noisy blood marker measurements for feedback. Instead of discretizing the problem with a discrete Markov Decision Process, we apply the Partially-Observed Monte-Carlo Planning algorithm to solve the continuous-time, continuous-state problem, leveraging the near-deterministic nature of cancer progression. Our approach, tested on multiple myeloma patient data, outperforms exact solutions of the discrete model and allows greater flexibility in cost function modeling, enabling patient-specific follow-ups. This method can also be adapted to other diseases.

Indexed as

AlgorithmsMarkov ChainsMonte Carlo MethodMultiple MyelomaDisease ProgressionFollow-Up StudiesHumansPrecision MedicineQuality of Life

Identifiers

PMID39700101
PMCPMC11658637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.